Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
2 reports, 1 independent
Updated Aug 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA approval supports NDA submission in Aurora.
- Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.